Lexeo Therapeutics (LXEO) Accumulated Depreciation (2022 - 2026)

Lexeo Therapeutics has reported Accumulated Depreciation for 5 years, with the latest figure at $814000.0 in Q1 2026.

• Quarterly Accumulated Depreciation rose 52.43% year-over-year to $814000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $814000.0 (up 52.43% YoY) and the FY2025 annual result came in at $741000.0, up 56.33% from the prior year.
• Accumulated Depreciation improved to $814000.0 in Q1 2026 per LXEO's latest filing, from $741000.0 in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $814000.0 in Q1 2026 and troughed at $133000.0 in Q4 2022.
• A 5-year average of $520333.3 and a median of $530500.0 in 2024 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2023 and 2025: Accumulated Depreciation jumped 186.47% in 2023, then increased 9.51% in 2025.
• Over 5 years, Accumulated Depreciation stood at $133000.0 in 2022, then surged by 186.47% to $381000.0 in 2023, then gained by 24.41% to $474000.0 in 2024, then soared by 56.33% to $741000.0 in 2025, then gained by 9.85% to $814000.0 in 2026.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $814000.0, $741000.0, and $668000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.